Sallam M, et al. - In view of the information that Overall Survival (OS) in Small Cell Lung Cancer cases is not affected by dose intensity and dose density of first line Platinum and Etoposide (PE), and treating beyond 4 cycles -up to 6-, in cases responsive to and tolerant to systemic treatment has been recommended by current guidelines, researchers undertook this inquiry to quantify whether extended regimen would offer any clinical benefit in real-life patients treated with PE doublet. There were 241 patients with stage IV who had received 4 cycles (4c) and 69 had > 4c. Both groups had a median Duration of Response of 5 months. Median Progression Free Survival was 8 months (4c) vs 9 months (> 4c) and median OS was 11 vs 12 months. Overall, the extension of first line PE treatment in stage IV disease did not afford any clinical benefit. Until the report of the superiority of a longer regimen in a randomised study, limiting treatment to 4 cycles is supported.